According to Bloomberg.com, the twenty research firms currently covering AstraZeneca PLC have collectively assigned a rating of “Hold” as the average recommendation for the stock. This rating represents the consensus view of the research firms regarding the stock. One investment analyst has suggested selling the stock; six analysts have rated the stock as “hold,” and six analysts have rated the stock as “buy.” One analyst has recommended selling the stock. During the previous year, brokerages had the stock under coverage, and their average price estimate over the next 12 months was $7,567.75.
A variety of different equity analysts have been focusing their recent attention, as of late, on AZN shares. Berenberg Bank lowered their price objective for AstraZeneca from GBX 120 ($1.38) to GBX 118 ($1.36) in a research report published on Wednesday, October 19. StockNews.com debuted its coverage of AstraZeneca on Wednesday, October 12, with the publication of an article that served as the website’s debut. They suggested that an interested party purchase the company. TheStreet has lowered its previous rating of “b-” for AstraZeneca to a “c” in a public report on Tuesday, August 30. In a research report that was made public on September 7, Morgan Stanley moved AstraZeneca from the “overweight” category to the “equal weight” category. Finally, a research report published on September 15 by Credit Suisse Group indicated that the company has downgraded AstraZeneca from “outperform” to “neutral.”
On Friday, the opening price of a share of AstraZeneca was $62.77 when trading got underway. The debt-to-equity ratio, the current ratio, and the quick ratio equal 0.67. In contrast, the current ratio is 0.96, and the quick ratio is 0.74. During the past year, the share price of AstraZeneca has fluctuated between the ranges of $52.65 and $71.70, with a low of $52.65. The company has a beta of 0.50, a market valuation of $194.51 billion, a PE ratio of 93.69, a price-to-earnings-growth ratio of 1.16, and a price-to-earnings-growth ratio of 1.16, investing in this business would be a wise decision. The price per share of the company’s stock has recently reached $56.75, and its 50-day and 200-day moving averages have reached $62.06, respectively.
Recent changes have been made to reflect the most recent holdings of the stock by hedge funds and other types of institutional investors. During the year’s second quarter, Better Money Decisions LLC opened a new position in AstraZeneca with an approximate value of $25,000. To finance the acquisition of AstraZeneca during the first three months of 2018, approximately $26,000 was placed in the investment portfolio managed by DB Wealth Management Group LLC. A 4,875.0% increase in the proportion of AstraZeneca stock that Parkside Financial Bank & Trust owns is the result of the company’s activity during the first three months of this year. The Parkside Financial Bank & Trust Company currently holds 398 shares, with a combined market value of $26,000. This is the result of the bank purchasing an additional 390 shares during the most recent quarter to increase its stake in the company. In addition, by investing approximately $28,000 in AstraZeneca during the second quarter, HHM Wealth Advisors LLC was able to initiate a new position in the company. During the third quarter, Hazlett Burt & Watson Inc. increased the amount of AstraZeneca stock owned by 129.5%, making this the last and most important point. After purchasing an additional 290 shares during the most recent quarter, Hazlett Burt & Watson Inc. now owns 514 shares worth $28,000.Institutional investors and hedge funds collectively hold 21.55 percent of the company’s total share capital.
AstraZeneca PLC is a biopharmaceutical company specializing in the research and development of prescription medications and their manufacture, distribution, and marketing. Crestor, Evrenzo, Farxiga, Bydureon, Byetta, BCise, Brilinta, and Brilique are some of the oncology-related drugs the company manufactures. Other oncology-related medications include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex.
Read More: Analysts’ average recommendation for AstraZeneca PLC (NASDAQ:AZN) is “Hold.”